Leerink Partners reiterates Outperform rating on Doximity stock ahead of earnings

Leerink Partners reiterated an Outperform rating and $73 price target on Doximity (NYSE:DOCS) ahead of its Q1 2026 earnings, citing the company's impressive 20% revenue growth, 90.2% gross margins, and the strategic potential of its AI Scribe solution. This bullish sentiment is largely echoed by Evercore ISI and BTIG, which upgraded the stock, highlighting strong demand for Doximity's platform in a stabilizing pharmaceutical market. While Wells Fargo maintained an Equal Weight rating, it acknowledged clients' plans to increase Doximity budgets by 16% for 2025, indicating continued strong engagement despite a conservative fiscal year 2026 guidance.

Analysis

Doximity (NYSE:DOCS) is experiencing a wave of positive analyst sentiment ahead of its fiscal first-quarter 2026 earnings report. The consensus among firms like Leerink Partners, Evercore ISI, and BTIG is overwhelmingly bullish, with two recent upgrades to Outperform/Buy and price targets ranging from $70 to $80. This optimism is underpinned by strong fundamental metrics, including a reported 20% revenue growth and exceptional gross margins of 90.2%. Analysts see the company's core value proposition—connecting pharmaceutical companies with prescribers—as a durable driver of growth. While Doximity's own fiscal 2026 guidance was viewed as conservative, this is being interpreted as a setup for potential upside, supported by a Wells Fargo report noting that clients plan to increase their Doximity budgets by 16% in 2025. Furthermore, catalysts such as the new AI Scribe solution are expected to deepen physician engagement and enhance the platform's value. The broader environment appears supportive, with a stabilizing risk profile in the pharmaceutical sector and encouraging spending trends cited from IQVIA. The primary note of caution comes from Wells Fargo, which maintains an Equal Weight rating and a $55 price target, highlighting lingering uncertainty in the overall pharmaceutical advertising market despite Doximity's client-specific strengths.

Key Decisions for Investors

• Given the strong analyst consensus and robust fundamentals, investors may view the company's conservative guidance as a potential source of an earnings beat and subsequent upward revision.
• Monitor the upcoming earnings call for management's commentary on the adoption of the new AI Scribe solution, as this is a key indicator of the company's ability to drive future growth and expand its ecosystem.
• Investors should weigh the bullish analyst upgrades and strong growth metrics against the risk of broader weakness in the pharmaceutical advertising market, a key uncertainty highlighted by Wells Fargo.
• Pay close attention to any updates on client budget allocations for 2025 and beyond, as the reported 16% planned increase is a critical data point supporting the bull case against a backdrop of conservative company guidance.